SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

______________

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

(Continued on following pages)

Item 1(a).	Name of Issuer:
	Vir Biotechnology, Inc.
Item 1(b).	Address of Issuer’s Principal Executive Offices:
	499 Illinois Street, Suite 500, San Francisco, California 94158.
Item 2(a).	Name of Person Filing:
	This Schedule 13G is being filed by the Alaska Permanent Fund Corporation with respect to the Common Stock, par value $0.0001 per share or Vir Biotechnology, Inc.
Item 2(b).	Address of Principal Business Office or, if None, Residence:
	The address of the principal business office of the Reporting Person is 801 West 10th Street, Suite 302, Juneau, Alaska, 99801.
Item 2(c).	Citizenship:
	The Reporting Person is the Alaska Permanent Fund Corporation, acting for and on behalf of the funds which the Alaska Permanent Fund Corporation is designated by Alaska Statutes 37.13 to manage and invest.
Item 2(d).	Title of Class of Securities:
	Common Stock, par value $0.0001 per share.
Item 2(e).	CUSIP Number:
	92764N 102
Item 3.	If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
	Not applicable.
Item 4.	Ownership.

	(a)	Amount beneficially owned:
	(i)	The Reporting Person directly owns 1,500,000 shares of the Issuer’s common stock.
	(ii)	Yukon Investors, LLC directly owns 3,333,333 shares of the Issuer’s common stock. The Reporting Person is a member of Yukon Investors, LLC, and may be deemed to beneficially own the shares held by it.
	(iii)	Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P. directly own 722,223 shares of the Issuer’s common stock. The Reporting Person is a limited partner in each of Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P. and may be deemed to beneficially own the

			shares held by such funds.
	(b)	Percent of class:
		See Row 11 of the cover page for the Reporting Person.
	(c)	Number of shares as to which the Reporting Person has:
		(i)	Sole power to vote or to direct the vote
			See Row 5 of the cover page for the Reporting Person.
		(ii)	Shares power to vote or to direct the vote:
			See Row 6 of the cover page for the Reporting Person.
		(iii)	Sole power to dispose or to direct the disposition of:
			See Row 7 of the cover page for the Reporting Person.
		(iv)	Shared power to dispose or to direct the disposition of:
			See Row 8 of the cover page for the Reporting Person.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:  December 5, 2019

[Signature page to Schedule 13G]